Avodart Cost in New Jersey 2026: What You Will Actually Pay for Dutasteride

What Is Dutasteride and Why Are New Jersey Patients Asking About Cost?

Dutasteride is a dual 5-alpha-reductase inhibitor that blocks both type I and type II isoenzymes, reducing serum dihydrotestosterone (DHT) by roughly 90 to 95 percent, compared to the approximately 70 percent reduction achieved by finasteride, which blocks only type II [1]. The FDA approved dutasteride 0.5 mg (brand name Avodart, originally marketed by GlaxoSmithKline) for benign prostatic hyperplasia in 2001 [2]. Physicians in New Jersey also prescribe it off-label for androgenetic alopecia (male pattern hair loss), a use supported by randomized controlled trial data.

Eun et al. conducted a 24-week, placebo-controlled RCT (N=153) and found dutasteride 0.5 mg daily produced statistically significant increases in total and anagen hair counts compared with placebo (P<0.001) and outperformed finasteride 1 mg on several hair-density metrics [3]. That efficacy profile drives demand well beyond the BPH population, which means a large share of New Jersey patients paying out of pocket need a clear picture of their options.

Prices vary enormously depending on whether you fill brand-name Avodart, a generic version, or a compounded preparation, and whether you use insurance, Medicaid, a manufacturer coupon, or a pharmacy discount card. The sections below break down each pathway with real 2026 numbers.

Brand-Name Avodart Price in New Jersey

The manufacturer list price for Avodart in New Jersey sits at approximately $290 per month for a 30-capsule supply of 0.5 mg in 2026. Almost no cash-paying patient pays this figure. The list price is the starting point for insurer negotiations and savings-card calculations, not a realistic out-of-pocket number for most people.

Patients with commercial insurance who have a formulary tier placing Avodart as a preferred brand may pay $30 to $80 per fill after the plan's negotiated discount, though many plans in New Jersey now exclude brand Avodart entirely and substitute the generic. Checking your specific plan's formulary at its member portal before you pick up a prescription will prevent surprise charges at the pharmacy counter.

GSK's patient-assistance and savings-card programs have historically reduced brand copays for eligible commercially insured patients, but program terms change annually. The GSK website and the NeedyMeds database [4] are reliable starting points for confirming current eligibility. New Jersey residents with household incomes up to 400 percent of the federal poverty level may qualify for manufacturer assistance that brings monthly cost near zero.

Generic Dutasteride Price in New Jersey

Generic versions are the dominant cost-reduction tool. At major New Jersey retail chains and independent pharmacies using a GoodRx, RxSaver, or Blink Health card, generic dutasteride 0.5 mg typically runs $20 to $30 per month in 2026, with $25 per month as a reliable benchmark [5]. Some warehouse club pharmacies (Costco, BJ's Wholesale) offer generic dutasteride closer to $15 to $18 per month without any coupon.

Price variation across the state is real. A 2023 FDA analysis of generic drug pricing found that switching from brand to generic produces average savings of 80 to 85 percent at the point of dispensing [6]. For dutasteride specifically, that arithmetic means moving from ~$290 brand to ~$25 generic, a difference of about $3,180 per year.

Generics approved under ANDA (Abbreviated New Drug Application) carry the same bioequivalence standards as the brand. The FDA maintains a list of approved dutasteride generics on its Orange Book database [7]. Patients who were previously stable on brand Avodart can expect the same clinical effect from an AB-rated generic.

Compounded Dutasteride in New Jersey: Legality and Pricing

Compounded dutasteride is legal in New Jersey when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber [8]. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, requiring that compounds be made for individual patients and not in bulk for general sale [9].

New Jersey does not impose additional state-level bans on compounding dutasteride beyond federal 503A requirements. The compound cannot contain a drug on the FDA's list of commercially available drug products that present demonstrable difficulties for compounding (the "difficult to compound" list), and dutasteride does not appear on that list as of mid-2025.

Compounded dutasteride in New Jersey typically costs approximately $40 per month, sitting between the $25 generic retail price and the $290 brand list price. Compounding is chosen by patients who need alternative dose strengths (for example, topical formulations being studied for hair loss), specific excipient-free formulations for allergy reasons, or combination products not commercially available. The clinical evidence base for compounded topical dutasteride specifically is still developing; a 2022 review in the Journal of the American Academy of Dermatology noted that topical 5-alpha-reductase inhibitors showed promise but that well-powered RCTs were lacking at that time [10].

Patients should verify that any 503A pharmacy they use holds a current New Jersey Board of Pharmacy license and complies with USP <795> non-sterile compounding standards [11].

New Jersey Medicaid Coverage for Dutasteride

New Jersey Medicaid covers dutasteride with prior authorization (PA) for FDA-approved indications, primarily BPH [12]. PA requirements typically ask the prescriber to document a diagnosis consistent with BPH (International Prostate Symptom Score, prostate volume, or PSA data), a trial of alpha-blocker therapy if applicable, and absence of contraindications.

Off-label use for androgenetic alopecia is generally not covered by NJ Medicaid without an exceptional circumstances justification, because Medicaid formulary decisions follow CMS guidance that off-label uses require compendia support (e.g., DRUGDEX, Clinical Pharmacology) or published peer-reviewed evidence sufficient to alter standard of care [13]. Prescribers seeking off-label Medicaid coverage should submit supporting literature including the Eun et al. RCT [3] and the larger JAAD systematic reviews alongside the PA request.

Managed Medicaid plans operating in New Jersey (such as Horizon NJ Health, AmeriHealth NJ, and WellCare NJ) may have slightly different PA criteria than fee-for-service Medicaid. Patients should request the specific formulary and PA form from their managed care plan rather than assuming the base Medicaid policy applies.

The New Jersey Division of Medical Assistance and Health Services (DMAHS) administers the Medicaid preferred drug list (PDL) and updates it quarterly [14]. Generic dutasteride is listed as preferred under the 5-alpha-reductase inhibitor class on the most recent PDL review, meaning PA is the only additional step once a covered BPH diagnosis is documented.

Commercial Insurance Coverage for Avodart in New Jersey

Most commercial plans available through the NJ marketplace, employer groups, and the Federal Employee Health Benefits Program include generic dutasteride on their formulary at tier 1 or tier 2. Tier 1 generics typically carry $0 to $15 copays under standard New Jersey commercial plans. Brand Avodart, if listed at all, usually falls on tier 3 or tier 4, generating $50 to $150 copays depending on the plan design [15].

Step therapy protocols are common. An insurer may require a documented 90-day trial of an alpha-blocker (tamsulosin, alfuzosin) before approving dutasteride for BPH. For hair loss, most commercial plans classify treatment as cosmetic and exclude coverage outright, making generic cash-pay or compounded dutasteride the practical route for that indication.

The Affordable Care Act essential health benefits framework does not mandate coverage for BPH medications specifically, so coverage genuinely varies by plan [16]. Employees with access to an HSA or FSA can use those pre-tax dollars to purchase generic dutasteride, effectively reducing the after-tax cost by 22 to 37 percent depending on their marginal federal income tax bracket.

How to Use Savings Cards and Discount Programs in New Jersey

Several layered strategies consistently lower the price of dutasteride in New Jersey:

GoodRx and RxSaver cards. Free to obtain, these cards work at virtually every New Jersey retail pharmacy. Entering dutasteride 0.5 mg, 30 capsules at a NJ ZIP code on GoodRx in 2026 returns prices ranging from approximately $18 at Costco to $32 at CVS, depending on location [5]. Cards cannot be combined with insurance on the same claim but can be used on any cash-pay prescription.

Manufacturer savings programs. GSK's Avodart savings card historically covered commercially insured patients up to a monthly cap. The NeedyMeds database [4] and the manufacturer's dedicated portal list current program terms. Patients not covered by government insurance (Medicare, Medicaid, TRICARE) are generally eligible.

NJ Pharmaceutical Assistance to the Aged and Disabled (PAAD). New Jersey's PAAD program assists seniors and disabled residents with fixed incomes in covering prescription copays [17]. Eligible enrollees pay a fixed copay per prescription regardless of the drug's retail price. PAAD income eligibility thresholds are adjusted annually; the 2026 single-person threshold sits at approximately $27,000 per year.

State Pharmaceutical Assistance Program (SPAP). New Jersey's SPAP coordinates with Medicare Part D to reduce out-of-pocket costs for dual-eligible residents, which may include dutasteride if covered under a Part D plan's formulary [18].

340B program. Federally qualified health centers (FQHCs) and certain safety-net hospitals in New Jersey can dispense 340B-priced dutasteride to qualifying low-income patients, often at near-zero cost [19].

Telehealth Prescribing of Dutasteride in New Jersey

Telehealth prescribing of dutasteride is legal in New Jersey for both BPH and off-label hair loss indications, provided the prescriber holds a valid New Jersey medical license and completes an appropriate clinical evaluation [20]. New Jersey's telehealth laws require that a prescriber establish a valid patient-physician relationship, which can occur via synchronous audio-video visit, before issuing a Schedule-exempt (non-controlled) medication like dutasteride.

Dutasteride is not a controlled substance, so the Ryan Haight Act restrictions that apply to controlled-substance telehealth prescribing do not limit dutasteride orders [21]. A prescribing provider conducting an NJ telehealth visit must still perform an adequate history and, for BPH, should document relevant lower urinary tract symptoms and baseline PSA where appropriate per American Urological Association (AUA) guidelines [22].

HealthRX and similar telehealth platforms operating in New Jersey can connect patients with licensed NJ clinicians who can evaluate, prescribe, and coordinate pharmacy fulfillment for dutasteride, often within 24 to 48 hours of an initial visit. Prescriptions can be routed to a local NJ retail pharmacy for generic fulfillment at ~$25 per month or to a licensed 503A compounding pharmacy for specialty formulations at ~$40 per month.

Clinical Pharmacology: Why Dose and Duration Matter for Cost Planning

Understanding how dutasteride works helps patients plan realistic treatment timelines and avoid premature discontinuation, which is one of the most common cost-related mistakes.

Dutasteride 0.5 mg taken orally once daily produces maximum DHT suppression (approximately 94 percent reduction) within two weeks of consistent use [1]. However, clinical benefits in BPH, including International Prostate Symptom Score improvement and prostate volume reduction, take three to six months to manifest fully. The COMBAT trial (N=4,844) showed that combination dutasteride plus tamsulosin produced significantly greater symptom improvement than either agent alone at 24 months, with an absolute reduction in AUA-SI score of 8.0 points versus 6.2 for tamsulosin monotherapy (P<0.001) [23].

For androgenetic alopecia, the Eun et al. 24-week trial showed measurable hair-density gains by 12 weeks, but the most substantial improvements accumulated between 12 and 24 weeks [3]. A 2020 systematic review in the Journal of the American Academy of Dermatology covering 22 trials of oral 5-alpha-reductase inhibitors for hair loss found that treatment durations shorter than six months consistently underestimated final efficacy [24].

Patients discontinuing after two or three months because they "aren't seeing results" are doing so before the drug has had adequate time to work, wasting their initial investment and losing whatever early benefit had accumulated. The practical cost implication is that a realistic minimum trial is six months, totaling roughly $150 at the $25/month generic cash price. That is a far smaller commitment than many patients assume.

PSA Monitoring and Lab Cost Considerations in New Jersey

Dutasteride suppresses PSA by approximately 50 percent after six months of use [2]. Clinicians following patients for prostate cancer screening need to double the measured PSA value to estimate the true underlying PSA on dutasteride. Failure to account for this can produce false-negative prostate cancer screens.

The American Cancer Society and AUA recommend establishing a baseline PSA before starting dutasteride in men over 50 or those with elevated prostate cancer risk [22]. A baseline PSA draw and an annual follow-up PSA are standard practice. In New Jersey, a standalone PSA lab draw costs approximately $15 to $40 with discount laboratory pricing (LabCorp or Quest direct-pay), or may be covered at zero cost-share under most ACA-compliant commercial plans as a preventive service for men 55 to 69 [25].

Adding lab costs into the total cost-of-care calculation for dutasteride therapy gives a more complete picture: approximately $300 to $350 per year for generic dutasteride at $25/month plus one annual PSA draw.

Comparing All NJ Dutasteride Cost Pathways Side by Side

The table below summarizes the realistic monthly out-of-pocket cost for each access pathway available to New Jersey patients in 2026:

| Pathway | Estimated Monthly NJ Cost | |---|---| | Brand Avodart, no coupon, no insurance | ~$290 | | Brand Avodart, commercial insurance tier 3 | $50, $150 | | Generic dutasteride, commercial insurance tier 1 | $0, $15 | | Generic dutasteride, cash + GoodRx | ~$25 | | Generic dutasteride, PAAD-eligible senior | Fixed low copay (~$5, $7) | | Compounded dutasteride, 503A pharmacy | ~$40 | | NJ Medicaid (BPH, PA approved) | $0, $3 copay | | 340B program (qualifying FQHC) | Near $0 |

The single fastest action any NJ patient without insurance can take is to download a free GoodRx card and ask the pharmacist to run it before paying. That one step converts a $290 Avodart claim into a ~$25 generic dutasteride transaction at virtually every pharmacy in the state.

Side Effects That May Affect Your Decision to Continue Treatment

Dutasteride's side-effect profile directly affects long-term adherence and therefore total treatment cost. The most clinically significant adverse effects are sexual in nature: decreased libido reported in approximately 3 to 5 percent of patients, erectile dysfunction in 1 to 5 percent, and ejaculatory disorders in 1 to 4 percent in clinical trials [2]. Most sexual side effects appeared within the first three months in the ARIA3001 and ARIA3002 registration trials and resolved after discontinuation in the majority of affected patients.

Post-finasteride syndrome (PFS) and the analogous dutasteride concern have been the subject of ongoing investigation. The FDA added a label update in 2012 requiring 5-alpha-reductase inhibitors to warn about persistent sexual side effects after discontinuation [26]. Patients concerned about this risk should discuss it directly with their prescriber before initiating therapy.

A small increase in high-grade prostate cancer was observed in the REDUCE trial (N=8,231), where dutasteride was associated with a statistically significant increase in Gleason score 8 to 10 tumors (0.5% vs. 0.5%, absolute risk small but relative risk elevated), leading to an FDA label update in 2011 [2]. This signal contributed to the FDA declining to approve dutasteride for prostate cancer chemoprevention. The clinical significance remains debated, but it underscores the importance of ongoing PSA and urologic monitoring during treatment [27].